This release summarizes a study comparing how three newer anticoagulants performed in preventing stroke and systemic embolism among frail patients compared to warfarin. Systemic embolism refers to a blood clot that causes blockage of blood flow. The 2,600-plus patients analyzed in the study all had non-valvular atrial fibrillation (NVAF). NVAF refers to irregular heart rhythm that is not caused by valvular heart disease.
The 2-year study looked at insurance claims data to analyze patient outcomes from different drugs. According to researchers, the study showed that the patients experienced fewer strokes and systemic embolism when treated with rivaroxaban (brand name Xarelto, manufactured by Janssen) compared to those taking warfarin or other anticoagulants (apixaban and dabigatran). The news release neglected to mention potential biases in this type of research, such as the lack of randomization among compared medications. Importantly, the scientific paper this release is based on compared three of the newer anti-coagulants to warfarin but did not compare them to each other, thus making it hard to determine if one truly was “better” than the others.
Ideally, research can help determine which, among several therapies, can reduce stroke or systematic embolism in frail patients with non-valvular atrial fibrillation. This type of research using matched cohorts of patients sounds very promising but also has many potential biases, mainly the lack of randomization. Appropriate caveats need to be considered about whether such a study can definitively determine the comparative value of these drugs.
No costs were mentioned and it is a significant factor, seeing as warfarin is very inexpensive and produces an anticoagulant effect that is reversible, a characteristic not available with the other anticoagulants.
The release relies solely on relative numbers in describing the benefits: “long-term XARELTO® use reduced the risk of stroke and systemic embolism by 32 percent and ischemic stroke alone by 31 percent compared to warfarin, with no significant increase in major bleeding.”
It’s a major omission in the release to not report the absolute numbers. According to Table 3 in the published study, out of 2,635 total patients, 39 of those on rivaroxaban suffered a stroke or systemic embolism compared to 49 patients on warfarin. This makes the absolute differences in these combined events to be 1.48% (for rivaroxaban) and 1.86% (for warfarin). The difference of 0.43% means that the number needed to treat to show a benefit is 233. In other words: If you switch 233 patients from warfarin to rivaroxaban, then at 1 year you would prevent one stroke whereas the other 232 patients would remain stroke-free regardless. At 2 years, the absolute risk reduction was a bit higher at 0.98%.
The main risk with these anti-coagulants is bleeding and the release mentions bleeding as a main complication. It also comments on the data of major bleeds which was the main safety endpoint of the paper.
The published study provides many appropriate cautions about the limitations of this research but unfortunately those details didn’t make it into the news release.
For example: “As a retrospective analysis of claims data, this study has limitations worthy of discussion. First, both misclassification (measurement error) and selection bias (selection of patients in a nonrandomized fashion) are always important limitations in claims database studies and may impact a study’s internal validity.”
Also: “propensity score matching can generate cohorts that are comparable in key characteristics, [yet] only those variables measured in MarketScan databases could be used for matching in this analysis. Therefore, regardless of the sophistication of the methodology and the number of variables used in developing propensity scores, residual confounding cannot be excluded.”
Also there were helpful notes about possibly underpowering the study due to the small sample size of the patient groups. All of these factors should urge a cautious interpretation of results.
There is no disease mongering here. The release provides appropriate context on the numbers of Americans affected by non-valvular atrial fibrillation.
It’s assumed that this is a Janssen-sponsored drug trial since the company issued the release but it is not expressly stated.
The study was all about using different drug therapy alternatives in trying to reduce the risk of strokes in certain frail patients. While the release didn’t provide the preferred absolute numbers (see Benefits criteria) it did cite some comparisons with some different drugs.
Many people would know these drugs are available in the US but that point isn’t made explicitly in the news release. However, it does state that the patient data came from a company that sells insurance claims data so a savvy reader would know that the drugs are all FDA approved and on the market.
The release doesn’t make any specific claim about novelty, nor does it acknowledge that there are many other studies, even some randomized trials, comparing these newer anticoagulant agents agents to warfarin.
It was unjustified use of language to use the term “significant” when it’s not clear that the results of the study proved the performance of Xarelto compared to other anticoagulants was “statistically significant.”
Systematic, Criteria-Driven
The @nytimeswell effort is shown to be unwell once again.
There's pervasive media bias toward hyping treatment benefits while neglecting negative results & harms.
Big part of this is reliance on experts with financial &/or intellectual conflicts of interest.
Att'n journalists: Use this list 100 independent experts to correct imbalance https://t.co/Twzc1Sp8Vw
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like